Testing glofitamab plus selinexor for relapsed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have CD20-positive diffuse large B-cell lymphoma that has relapsed or not responded after at least two previous treatments.
- You have a tumor that can be measured on scans.
- You are in generally good health (able to take care of yourself, up and about at least half the day).
- You have not had treatment with a CD20/CD3 bispecific antibody or an XPO1 inhibitor before.
- You do not have active infections like HIV, hepatitis B or C, or serious heart or brain problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a new combination: selinexor (a pill that targets cancer cells) plus a standard chemotherapy regimen (R-GDP) for people with relapsed or refractory DLBCL that has a specific genetic change in the TP53 gene. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests a new combination of three drugs (EZH2 inhibitor, glofitamab, and gemcitabine/oxaliplatin) for patients with diffuse large B-cell lymphoma that has stopped responding to or come back after prior treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.